Use of biomarkers of heavy drinking in health care practice
Use of biomarkers of heavy drinking in health care practice
复制标题
DOI：
10.1093/milmed/168.5.364
复制
发表时间：
2003-05-01
影响因子：
1.2
通讯作者：
Allen, JP
中科院分区：
文献类型：
--
作者：
Allen, JP
有几种生化测试可用于筛查患者是否大量饮酒。其中大多数(例如肝功能测试和巨噬细胞体积)的升高是由于酒精对器官或器官功能的不利影响。然而，缺乏碳水化合物的转铁蛋白似乎因为酒精或其代谢物的直接作用而升高。生物标志物的第二个有价值的贡献是在戒酒过程中识别复发事件，这些事件要么不会自愿报告，要么只会在很晚的时候才报告。最后，在治疗中根据患者的生物标志物价值和治疗过程中他们的变化向患者提供反馈可以增强动力，这是从酒精问题中恢复的关键组成部分。目前的文章提供了在卫生保健实践中常规使用大量饮酒的生物标记物的临床理由，并就如何最好地使用它们提出了建议。
Several biochemical tests are available to screen for heavy drinking in patients. Most of these (e.g., liver function tests and macrocytic volume) rise due to adverse effects of alcohol on organs or the organ's functions. Carbohydrate-deficient transferrin, however, seems to elevate because of the direct action of alcohol or one of its metabolites. A second valuable contribution of biomarkers is identification of relapse events in recovering alcoholics that either would not be voluntarily reported or reported only much later. Finally, providing feedback to patients in treatment based on their biomarker values and changes in them during the course of treatment can enhance motivation, a key component in recovery from alcohol problems. The current article offers a clinical rationale for routine use of biomarkers of heavy drinking in health care practice and proposes recommendations on how they might be best used.